Lexicon Pharmaceuticals, Inc. (LXRX) compared with its closest peers (OCUL, XOMA, QTTB, PTGX, AGIO). Peer set by Pharmaceutical Products; 10 comparable drugmakers. First-party data.
Ocular Therapeutix, XOMA Royalty, Q32 Bio, Protagonist Therapeutics, Agios Pharmaceuticals, Nektar Therapeutics, Aquestive Therapeutics, Cumberland Pharmaceuticals, Xilio Therapeutics and Palvella Therapeutics share Lexicon Pharmaceuticals's sub-industry, pharmaceutical makers.
| Company | Market Cap | P/E |
|---|---|---|
| Ocular Therapeutix, Inc. (OCUL) | $2.43B | -8.5 |
| XOMA Royalty Corp. (XOMA) | $505.65M | 16.8 |
| Q32 Bio Inc. (QTTB) | $270.79M | 1.4 |
| Protagonist Therapeutics, Inc. (PTGX) | $9.93B | -42.6 |
| Agios Pharmaceuticals, Inc. (AGIO) | $1.97B | -3.8 |
| Nektar Therapeutics (NKTR) | $2.53B | -4.3 |
| Aquestive Therapeutics, Inc. (AQST) | $583.63M | -8.4 |
| Cumberland Pharmaceuticals Inc. (CPIX) | $114.10M | -20.5 |
| Xilio Therapeutics, Inc. (XLO) | $52.68M | -0.2 |
| Palvella Therapeutics, Inc. (PVLA) | $2.04B | -28.2 |
| Sector P/E (Healthcare) | 21.7 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
LXRX overview · LXRX earnings · LXRX financials · LXRX KPIs · LXRX documents · LXRX ownership
Data sourced from U.S. SEC EDGAR filings and market data. Not personalized investment advice.